Compared with irbesartan, there was a greater reduction in UP/C with sparsentan, and a larger proportion of patients achieved FPRE. The figure illustrates.

Slides:

Advertisements

Similar presentations

Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study) Lambers Heerspink,

Advertisements

Irbesartan Diabetic Nephropathy Trial (IDNT) Collaborative Study Group N Eng J Med 345: , 2001 Edmund J. Lewis, M.D. Muehrcke Family Professor of.

MULTICENTER RANDOMIZED CLINICAL TRIAL OF FSGS IN CHILDREN AND YOUNG ADULTS J Gassman, R Fine, A Friedman, D Gipson, T Greene, R Hogg, F Kaskel, M Moxey-Mims,

Copyright © 2003 American Medical Association. All rights reserved.

Volume 59, Issue 3, Pages (March 2001)

A Phase 2, Double-Blind, Placebo-Controlled, Randomized Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis

Patient disposition for the double-blind study period.

Clinical Trial of Vadadustat in Patients with Anemia Secondary to Stage 3 or 4 Chronic Kidney Disease Martin et al. Am J Nephrol 2017;45: (DOI:

Pioglitazone treatment prevents TRPC6 overexpression and podocyte injury in the adriamycin (ADRIA)–induced nephropathy rat model for FSGS. ADRIA-induced.

Relationship between urinary TNF-α and RANTES excretion

Differential expression of select miRNAs was validated in a second cohort of patients. Differential expression of select miRNAs was validated in a second.

Relationship between SBP levels and the urinary excretion of TNF-α (A), RANTES (B), and thiobarbituric acid–reacting substances (malondialdehyde [MDA];

Pedigrees of the families of patients 1 and 2 show that the clinical phenotype co-segregates with compound heterozygous CLDN10 variants. Pedigrees of the.

Schematic representations of DGKE protein and mRNA illustrating the relative positions of all pathogenic mutations reported to date. Schematic representations.

ACR20, ACR50, and ACR70 response rates during the 12-week study of Japanese patients with rheumatoid arthritis treated with baricitinib or placebo. ACR20,

Several microRNAs are differentially expressed in the glomeruli between different types of kidney disease. Several microRNAs are differentially expressed.

The proportion of DCD donor kidneys discarded was correlated with the proportion of NBD donor kidneys discarded within DSAs (Pearson correlation coefficient.

Paul D. Thompson, MD, John Rubino, MD, Matthew J. Janik, MD, Diane E

Volume 84, Issue 2, Pages (August 2013)

Effects of reslizumab on asthma quality of life questionnaire (AQLQ) score in Global Initiative for Asthma (GINA) Step 4 and 5 patients. Effects of reslizumab.

Q.A. Truong et al. Circ Cardiovasc Qual Outcomes 2011;4:

Volume 54, Issue 4, Pages (October 1998)

Double-blind, randomized, multicenter phase 2 study of SC411 in children with sickle cell disease (SCOT trial)‏ by Ahmed A. Daak, Carlton D. Dampier, Beng.

R. Agarwal, A.R. Rizkala, M.O. Kaskas, R. Minasian, J.R. Trout

Disease activities evaluated as a comparison between abatacept plus MTX and placebo plus MTX groups. Disease activities evaluated as a comparison between.

Volume 79, Issue 6, Pages (March 2011)

Volume 80, Issue 8, Pages (October 2011)

Volume 85, Issue 3, Pages (March 2014)

Use of a probioitic to decrease enteric hyperoxaluria

Aggressive blood pressure reduction and renin–angiotensin system blockade in chronic kidney disease: time for re-evaluation? Pantelis A. Sarafidis, Luis.

Classification by HtTKV0 and age at HtTKV0 predicts the change in eGFR over time in class 1 patients. Classification by HtTKV0 and age at HtTKV0 predicts.

Trend of overall improvement in CKD risk categories after bariatric surgery using year 1 post-surgery as baseline. Trend of overall improvement in CKD.

Patient disposition. Patient disposition. AE, adverse event. *One patient died during the follow-up period. ^Four of the 12 discontinuations of treatment.

(A through C) Mean eGFR during follow-up according to treatment assignment in patients with normoalbuminuria (A), microalbuminuria (B), and macroalbuminuria.

Correcting hyperkalemia in DCT-CA-SPAK mice with a low K diet corrects differences in ammonia excretion and inducing hyperkalemia in WT mice, with the.

PTA for AUC/MIC ratio ≥800 for each 48-hour AUC: AUC0 to 48 (A), AUC48 to 96 (B), and AUC96 to 144 (C). PTA for AUC/MIC ratio ≥800 for each 48-hour AUC:

Scatterplots showing the association between the three peritoneal equilibration test (PET) parameters. Scatterplots showing the association between the.

Additional efficacy outcomes for the 12-week study of Japanese patients with rheumatoid arthritis treated with baricitinib or placebo. Additional efficacy.

The insulin tolerance test at week 18.

Vitamin K2 supplementation reduces dp-ucMGP but not dp-cMGP levels in dialysis patients. Vitamin K2 supplementation reduces dp-ucMGP but not dp-cMGP levels.

The course of the remnant kidney model in mice

(A) Urinary L-FABP (ULFABP) values in eight participants who had more than 5 µg/g creatinine (Cr) at the start of the study, at baseline and after treatment.

Volume 63, Pages S13-S16 (February 2003)

Lifestyle intervention was associated with improved cardiorespiratory fitness. Lifestyle intervention was associated with improved cardiorespiratory fitness.

Proteinuria trend versus time for seven patients who achieved remission with adrenocorticotropic hormone (ACTH). Proteinuria trend versus time for seven.

Volume 62, Issue 5, (November 2002)

Volume 68, Issue 3, Pages (September 2005)

Ionized-to-total magnesium (Mg) and calcium (Ca) ratios are lower in patients on hemodialysis than those in patients not on dialysis. Ionized-to-total.

The development of regional ventricular dysfunction as measured by regional wall motion abnormalities (RWMA; abnormal regions) was associated with a greater.

Many anticancer drugs are dosed according to body surface area (BSA), but they are dose adjusted according to measures of absolute kidney function (i.e.,

ACR responses: (A) responses at Week 52 and Week 104

Effect of empagliflozin on efficacy parameters at week 18.

Volume 73, Issue 11, Pages (June 2008)

Glycemic control and body weight over 52 weeks.

Serum bicarbonate increased by ≥3, ≥4, and ≥5 mEq/L in 52%, 39%, and 22% of patients, respectively, in the combined TRC101 dose group compared with 6%,

The proportions (and 95% CIs) of anti-CCP+/RF+, anti-CCP+/RF-, anti-CCP-/RF+ and anti-CCP-/RF- patients receiving tofacitinib 5 or 10 mg two times a day.

Distribution of percent consistent facility aspirin use.

Changes in 44-hour interdialytic systolic BP as a function of change in echocardiographic volume parameter. Changes in 44-hour interdialytic systolic BP.

New dialysis starts in the United States by year in patients with and without diagnosis of diabetes. New dialysis starts in the United States by year in.

Aliskiren, the orally effective renin inhibitor, provides antihypertensive efficacy at least equivalent to the ARB irbesartan in patients with hypertension.

Separation in achieved BP levels between the two intervention groups in the SPRINT participants with CKD. The broken line and open circles denote the intensive.

The best response for target lesions per patient for patients with target lesions assessed at baseline and at least 1 follow-up. The best response for.

Percent of patients with ASDAS inactive disease grouped by normal or elevated CRP at baseline through week 156. §p

Changes in urinary albumin excretion rate in relation to baseline (top), cross-sectional values of GFR (middle), and MABP (bottom) during treatment with.

Decreased urinary excretion of vascular endothelial growth factor in idiopathic membranous glomerulonephritis Eero O. Honkanen, Anna-Maija Teppo, Carola.

Patient H: changes in circulating sFlt-1 levels and corresponding parameters after two apheresis treatments. Patient H: changes in circulating sFlt-1 levels.

Study design. aPatients initially receiving tenapanor 30 mg twice a day were allowed to down-titrate weekly (stepwise 30 → 20 → 15 → 10 → 3 mg twice a.

Study design. Study design. Patients who completed the 8-week induction study and achieved clinical response-100 (decrease in Crohn's disease activity.

(A) Percentage of patients achieving remission or response at week 12 or 24 after initiating ova therapy. (A) Percentage of patients achieving remission.

Volume 77, Issue 2, Pages (January 2010)

Presentation transcript:

Compared with irbesartan, there was a greater reduction in UP/C with sparsentan, and a larger proportion of patients achieved FPRE. The figure illustrates the reduction in UP/C from baseline to week 8 for (A) all sparsentan doses for the EES and (B) 400 and... Compared with irbesartan, there was a greater reduction in UP/C with sparsentan, and a larger proportion of patients achieved FPRE. The figure illustrates the reduction in UP/C from baseline to week 8 for (A) all sparsentan doses for the EES and (B) 400 and 800 mg sparsentan doses for the EES. Reduction in UP/C from baseline to week 8 for (C) all sparsentan doses for the FAS and (D) 400 and 800 mg doses for the FAS. (E) Reduction in 24-hour urinary protein excretion for the EES. (F) Proportion of patients who achieved FPRE for the EES. *Geometric least squares mean percent change from baseline. P values for changes in UP/C from analysis of covariance. FPRE is defined as UP/C≤1.5 g/g and >40% reduction in UP/C. P value for FPRE obtained using the Fisher exact test. For the FAS analysis, patients with a missing UP/C value were imputed as zero. EES, efficacy evaluable set; FAS, full analysis set; FPRE, FSGS partial remission endpoint; FSGS, focal segmental glomerulosclerosis; UP/C, urinary protein-to-creatinine ratio. Howard Trachtman et al. JASN 2018;29:2745-2754 ©2018 by American Society of Nephrology